

**Press Release**

October 3, 2011

For further information:

Peter Friedli  
Neuhofstrasse 8  
8834 Schindellegi  
Tel: 044/283 29 00  
Email: [peter.friedli@friedlicorp.ch](mailto:peter.friedli@friedlicorp.ch)

**New Venturetec: Result expectation for the fiscal year 2010/2011 ended  
September 30, 2011**

Zug, October 3, 2011. New Venturetec ended its fiscal year 2010/11 per September 30, 2011. Based on the current valuations of the portfolio companies New Venturetec expects a consolidated net loss of approximately USD 6,800,000 or USD 1.36 per share. The reason for the loss is the decrease of the traded share price of Osiris Therapeutics from USD 7.28 per share to USD 5.12 per share in the reporting period. The estimated numbers could change materially during the course of the end year valuation process of the portfolio, which will be done in the coming weeks. The final annual financials, together with the annual report of New Venturetec 2010/11 will be published on November 9, 2011.

New Venturetec did not give any guidance on its performance for the fiscal year 2010/11 and has never done so in the past.

New Venturetec is a publicly traded Swiss investment company (SIX: NEV) which invests directly in venture capital companies in the area of biotechnology and technology in the USA.